APP Coordinating with FDA to Alleviate Critical Shortage of Propofol Injection in the United States

APP maintains its commitment to increasing supply of Diprivan to the US market. APP continues to work closely with the FDA to increase supply of other propofol products including the importation of PROPOVEN 1% (propofol) and initial shipments of APP propofol 20mL. As of February 1, 2010 PROPOVEN 1% (propofol) inventories have been depleted. APP recognizes that there continues to be a propofol shortage in the US market and is focused on increasing supply of all propofol sizes; including 20mL, 50mL and 100mL beginning February 2010. We believe this incremental supply, in combination with weekly Diprivan releases, will help alleviate shortages of propofol products.

To view the Dear Healthcare Professional Letter, click here. To view a clinical comparison of APP's DIPRIVAN^® and Fresenius Propoven click here. For a list of Frequently Asked Questions, click here.

Contact APP's Medical Information department at 1-800-551-7176 between the hours of 8 a.m. and 5 p.m. (CST), or e-mail appmedicalinfo@APPpharma.com if you have any questions about the safe and effective use of Fresenius Propoven 1% (propofol 1%).

If you have additional questions regarding product availability, please contact APP's Customer Service at 1-888-386-1300, Monday – Friday, between the hours of 7:00 a.m. and 6:00 p.m. (CST).

Important Information Regarding New USP Standard for Unfractionated Heparin On October 1, 2009, the implementation of the new USP monograph for unfractionated heparin will go into effect. The purpose of the USP monograph changes are to further assure the purity of the Active Pharmaceutical Ingredient (API) through specific assay tests and calibrate activity to align with the International Standard (IS) issued by the World Health Organization (WHO). As a proven leader in providing safe, efficacious and rigorously tested heparin products to the U.S. market, APP has always met or exceeded USP standards and will implement and meet the new USP standards. In order for customers to clearly differentiate product tested using the new USP standards, APP will be incorporating an "N" (for "new") after the expiration date on every vial. An example of the new vial label can be seen by clicking on this link. For more information on APP products, please contact Customer Service at (888) 386-1300 between the hours of 7:00 a.m. and 6:00 p.m. CT. For clinical and technical questions regarding APP products, please call the Medical Information and Safety Department at (800) 551-7176 between the hours of 8:00 a.m. and 5:00 p.m. CT or contact us via e-mail at APPMedicalInfoUSP@APPpharma.com.